Skip to main content

Advertisement

SpringerLink
Log in

Interstitial lung disease in systemic sclerosis

  • Review
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Lung involvement frequently complicates systemic sclerosis (SSc), provoking loss of quality of life and a poor expectation of survival. For this reason an early diagnosis of lung involvement is warranted: high-resolution computed tomography (HRCT), pulmonary function tests (PFT), lung scintigraphy with DTPA and bronchoalveolar lavage (BAL) are mandatory to define and follow-up pulmonary interstitium. Coughing and a sensation of breathlessness on exertion are the earliest symptoms of lung involvement. Lung involvement may be investigated with PFTs, which are non-invasive and require breathing into a tube via a mouthpiece. Forced vital capacity, which measures the total amount of air capable of being blown forcefully, and the diffusion capacity for carbon monoxide, a measure of how well oxygen diffuses into blood, are the most important functional measures. A routine chest X-ray may demonstrate fibrosis, but it is not very sensitive for detecting early or mild disease. For this reason, a HRCT scan is required. This non-invasive investigation provides images of multiple slices through the lung, from top (apex) to bottom (base), and can even detect lung involvement in early phases when no symptoms are present. 99mT-DTPA is recommended in those patients with isolated diffusion deficits on lung function tests and in addition to HRCT in confirming the suspicion of vascular disease rather than early fibrosing alveolitis. Bronchoscopy with BAL is an invasive test that also may provide information about the inflammatory status of the affected areas of the lung detected during HRCT. In order to detect alveolitis, it should be performed as early as possible, to start prompt immunosuppressive treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283–1289

    Article  PubMed  CAS  Google Scholar 

  2. D’Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46:428–440

    Article  PubMed  CAS  Google Scholar 

  3. Rossi GA, Bitterman PB, Ferrans VJ, Crystal RG (1985) Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Resp Dis 131:612–617

    PubMed  CAS  Google Scholar 

  4. Manoussakis MN, Constantopoulos SH, Gharoni AE, Moutsopoulos HM (1987) Pulmonary involvement in systemic sclerosis. Chest 92:509–513

    Article  PubMed  CAS  Google Scholar 

  5. Steen VA, Ziegler GL, Rodnan GP, Medsger TA Jr (1984) Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27:125–131

    Article  PubMed  CAS  Google Scholar 

  6. Visscher DW, Myers JL (2006) Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 3:322–329

    Article  PubMed  Google Scholar 

  7. Travis WD, King TE Jr, Bateman ED et al (2002) American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Resp Crit Care Med 165:277–304

    Google Scholar 

  8. Kim DS, Yoo B, Lee JS (2002) The major histopathologic pattern of pulmonary fibrosis in scleroderma is non specific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 19:121–127

    PubMed  Google Scholar 

  9. Bouros D, Wells AU, Nicholson AG (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Resp Crit Care Med 165:1581–1586

    Article  PubMed  Google Scholar 

  10. Fujita J, Yoshinouchi T, Ohtsuki Y et al (2001) Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 60:281–283

    Article  PubMed  CAS  Google Scholar 

  11. Nicholson AG, Colby TV, Dubois RM et al (2000) The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213–2217

    PubMed  CAS  Google Scholar 

  12. Flaherty KR, Travis WD, Colby TV et al (2001) Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164:1722–1727

    PubMed  CAS  Google Scholar 

  13. Guttadauria M, Ellman H, Emmanuel G (1977) Pulmonary function in scleroderma. Arthritis Rheum 20:1071–1079

    Article  PubMed  CAS  Google Scholar 

  14. Peters-Golden M, Wise RA, Hochberg MC et al (1984) Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 77:1027–1034

    Article  PubMed  CAS  Google Scholar 

  15. Steen VD, Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48:516–522

    Article  PubMed  Google Scholar 

  16. Steen VD, Medsger TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444

    Article  PubMed  CAS  Google Scholar 

  17. Morgan C, Knight C, Lunt M et al (2003) Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 62:146–150

    Article  PubMed  CAS  Google Scholar 

  18. Wells AU, Hansell DM, Rubens MB et al (1997) Fibrosing alveolitis in Systemic Sclerosis: indices of lung function in relation to extend of disease in computerised tomography. Arthritis Rheum 40:1229–1236

    PubMed  CAS  Google Scholar 

  19. Warrick JH, Bhalla M, Schabel SI, Silver RM (1991) High resolution computed tomography in early scleroderma lung disease. J Rheumatol 18:1520–1528

    PubMed  CAS  Google Scholar 

  20. Remy-Jardin M, Remy J, Wallaert B (1993) Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary tests and broncho-alveolar lavage. Radiology 188:499–506

    PubMed  CAS  Google Scholar 

  21. Ooi GC, Mok MY, Tsang KW (2003) Interstitial lung disease in systemic sclerosis. Acta Radiol 44:258–264

    Article  PubMed  CAS  Google Scholar 

  22. Desai SR, Veeraraghavan S, Hansell DM (2004) CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and non specific interstitial pneumonia. Radiology 232:560–567

    Article  PubMed  Google Scholar 

  23. O’Brodovich H, Coates G (1987) Pulmonary clearance of 99mTC-DTPA: a non invasive assessment of epithelial integrity. Lung 166:1–16

    Article  Google Scholar 

  24. Pantin CF, Valid SO, Sweatman M et al (1988) Measures of the inflammatory response in cryptogenetic fibrosing alveolitis. Am Rev Respir Dis 138:1234–1241

    PubMed  CAS  Google Scholar 

  25. Mogulkoc N, Brutsche MH, Bishop PW et al on behalf of the Greater Manchester Pulmonary Fibrosis Consortium (2001) Pulmonary 99mTc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 56:916–923

    Article  PubMed  CAS  Google Scholar 

  26. Wells AU, Hansell DM, Harisson NK et al (1993) Clearance of inhaled 99mTC predicts the clinical course of fibrosing alveolitis. Eur Resp J 6:797–802

    CAS  Google Scholar 

  27. Antoniou KM, Malagari K, Tzanakis N et al (2006) Clearance of technetium-99m-DTPA and HRCT findings in the evaluation of patients with idiopathic pulmonary fibrosis. BMC Pulm Med 6:4

    Article  PubMed  CAS  Google Scholar 

  28. White B, Moore WC, Wigley FM (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947–954

    PubMed  CAS  Google Scholar 

  29. Silver RM, Miller KS, Smith EA, Schabel SI (1990) Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 88:470–476

    Article  PubMed  CAS  Google Scholar 

  30. Witt C, Borgess AC, John M et al (1999) Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncholaveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 58:635–640

    Article  PubMed  CAS  Google Scholar 

  31. Wells AU, Hansell DM, Rubens MB et al (1994) Fibrosing alveolitis in systemic sclerosis: bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 150:462–468

    PubMed  CAS  Google Scholar 

  32. Clements P, Goldin J, Kleerup E et al (2004) Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 50:1909–1917

    Article  PubMed  Google Scholar 

  33. Kohno N, Akiyama M, Kyoizumi S et al (1988) Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 18:203–216

    PubMed  CAS  Google Scholar 

  34. Kohno N, Kyoizumi S, Awaya Y et al (1989) New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigene K1-6. Chest 96:68–73

    Article  PubMed  CAS  Google Scholar 

  35. Yamane K, Ihn H, Kubo M et al (2000) Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 27:930–934

    PubMed  CAS  Google Scholar 

  36. Sato S, Nagaoka T, Hasegawa M (2000) Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 200:196–201

    Article  PubMed  CAS  Google Scholar 

  37. Day AJ (1994) The C-type carbohydrate recognition domain (CRD) superfamily. Biochem Soc Trans 22:83–88

    PubMed  CAS  Google Scholar 

  38. Hermans C, Bernard A (1999) Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med 159:646–678

    PubMed  CAS  Google Scholar 

  39. Honda Y, Kuroki Y, Matsutsuura E et al (1995) Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 152:1860–1866

    PubMed  CAS  Google Scholar 

  40. Takahashi H, Kuroki Y, Tanaka K et al (2000) Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 162:258–263

    PubMed  CAS  Google Scholar 

  41. Yanaba K, Hasegawa M, Takehara K, Sato S (2004) Comparative study of serum surfactant protein D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 31:1112–1120

    PubMed  CAS  Google Scholar 

  42. Kodera M, Hasegawa M, Komura K et al (2005) Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 52:2889–2896

    Article  PubMed  CAS  Google Scholar 

  43. American Thoracic Society (1999) Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children. Am J Respir Crit Care Med 160:2104–2117

    Google Scholar 

  44. Kharitonov SA, Cailes JB, Black CM et al (1997) Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 52:1051–1055

    Article  PubMed  CAS  Google Scholar 

  45. Fajac I, Kahan A, Menkes CJ et al (1998) Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 16:547–552

    PubMed  CAS  Google Scholar 

  46. Paredi P, Kharitonov SA, Loukides S et al (1999) Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 115:1352–1356

    Article  PubMed  CAS  Google Scholar 

  47. Moodley YP, Lalloo UG (2001) Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung. Disease Chest 119:1449–1454

    Article  CAS  Google Scholar 

  48. Matucci-Cerinic M, D’Angelo S, Denton CP et al (2003) Assessment of lung involvement. Clin Exp Rheumatol 21[3 Suppl 29]:19–23

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine & Surgery Div Medicine I & Rheumatology AOUC, University of Florence, Florence, Italy

    O. Kaloudi, I. Miniati, S. Alari & M. Matucci-Cerinic

  2. Department of Medicine, Villa Monna Tessa, Viale Pieraccini 18, I-50139, Florence, Italy

    I. Miniati

Authors
  1. O. Kaloudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Miniati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Alari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Matucci-Cerinic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Miniati.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaloudi, O., Miniati, I., Alari, S. et al. Interstitial lung disease in systemic sclerosis. Int Emergency Med 2, 250–255 (2007). https://doi.org/10.1007/s11739-007-0075-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-007-0075-1

Keywords

Search

Navigation